Clinical stable systemic mastocytosis with interferon alpha 2b therapy

. Hubner C, Wedding U, Strater J, Limberg B, Stremmel W (Universitat Heidelberg. Friedrich Schiller Universitat, Jena and Universit2t Ulm, Germany). Clinical stable systemic mastocytosis with interferon alpha‐2b therapy (Case report). Systemic mastocytosis (SM) with progessive infiltration of variou...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 1997-06, Vol.241 (6), p.529-533
Main Authors: HÜBNER, C., WEDDING, U., STRÄTER, J., LIMBERG, B., STREMMEL, W.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Dermatology
Disease Progression
Drug Therapy, Combination
Glucocorticoids - therapeutic use
Humans
interferon
Interferon alpha-2
Interferon-alpha - therapeutic use
Leukocyte Count - drug effects
Male
Mastocytosis - classification
Mastocytosis - drug therapy
Mastocytosis - pathology
Medical sciences
Middle Aged
Pigmentary diseases of the skin
Prednisone - therapeutic use
Recombinant Proteins
systemic mastocytosis
urticaria pigmentosa
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:. Hubner C, Wedding U, Strater J, Limberg B, Stremmel W (Universitat Heidelberg. Friedrich Schiller Universitat, Jena and Universit2t Ulm, Germany). Clinical stable systemic mastocytosis with interferon alpha‐2b therapy (Case report). Systemic mastocytosis (SM) with progessive infiltration of various organs by mast cells is a rare disease with a mean survival of 2 years. So far there is no established therapy. We describe a patient with Stremmel W (Universitat Heidelberg. Friedrich progressive mastocytosis who had a clinical response to interferon alpha‐2b 3 times 5 Mio U sc three times a week. The response is stable 3 years after initiation of therapy and includes reduction of abdominal lymphadenopathy, ascites, decrease of serum and urinary histamine levels as well as pulmonary reticdonodular markings.
ISSN:0954-6820
1365-2796
DOI:10.1111/j.1365-2796.1997.tb00013.x